Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression.… Read more
Alaunos Therapeutics Inc (TCRT) - Total Assets
Latest total assets as of September 2025: $3.72 Million USD
Based on the latest financial reports, Alaunos Therapeutics Inc (TCRT) holds total assets worth $3.72 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Alaunos Therapeutics Inc - Total Assets Trend (2001–2024)
This chart illustrates how Alaunos Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Alaunos Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Alaunos Therapeutics Inc's total assets of $3.72 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 39.6% |
| Accounts Receivable | $5.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2024)
This chart illustrates how Alaunos Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alaunos Therapeutics Inc's current assets represent 100.0% of total assets in 2024, an increase from 31.8% in 2001.
- Cash Position: Cash and equivalents constituted 39.6% of total assets in 2024, up from 15.6% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 33.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Alaunos Therapeutics Inc Competitors by Total Assets
Key competitors of Alaunos Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Alaunos Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Alaunos Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Alaunos Therapeutics Inc is currently not profitable relative to its asset base.
Alaunos Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.92 | 4.30 | 7.11 |
| Quick Ratio | 2.92 | 4.30 | 7.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.76 Million | $ 2.72 Million | $ 112.22 Million |
Alaunos Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Alaunos Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.05 |
| Latest Market Cap to Assets Ratio | 2.07 |
| Asset Growth Rate (YoY) | -66.7% |
| Total Assets | $2.75 Million |
| Market Capitalization | $5.69 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Alaunos Therapeutics Inc's assets at a significant premium ( 2.07x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Alaunos Therapeutics Inc's assets decreased by 66.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Alaunos Therapeutics Inc (2001–2024)
The table below shows the annual total assets of Alaunos Therapeutics Inc from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.75 Million | -66.66% |
| 2023-12-31 | $8.26 Million | -87.28% |
| 2022-12-31 | $64.94 Million | -31.55% |
| 2021-12-31 | $94.86 Million | -35.18% |
| 2020-12-31 | $146.34 Million | +34.12% |
| 2019-12-31 | $109.11 Million | +14.80% |
| 2018-12-31 | $95.05 Million | -9.99% |
| 2017-12-31 | $105.61 Million | -0.70% |
| 2016-12-31 | $106.35 Million | -30.82% |
| 2015-12-31 | $153.72 Million | +239.82% |
| 2014-12-31 | $45.24 Million | -36.96% |
| 2013-12-31 | $71.75 Million | -13.97% |
| 2012-12-31 | $83.40 Million | -22.85% |
| 2011-12-31 | $108.11 Million | +75.73% |
| 2010-12-31 | $61.52 Million | +23.69% |
| 2009-12-31 | $49.74 Million | +295.58% |
| 2008-12-31 | $12.57 Million | -65.77% |
| 2007-12-31 | $36.73 Million | +24.45% |
| 2006-12-31 | $29.51 Million | +210.91% |
| 2005-12-31 | $9.49 Million | +45201323.81% |
| 2004-12-31 | $21.00 | -36.36% |
| 2003-12-31 | $33.00 | -93.41% |
| 2002-12-31 | $501.00 | -82.63% |
| 2001-12-31 | $2.88K | -- |